Do you want to read an article? Please log in or register.
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial
Stroke
Related content
Further Publications NeurologyFurther Publications Psychiatry
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial
Lancet Neurol.
Selim M, Foster LD, Moy CS, Xi G, Hill MD, Morgenstern LB, Greenberg SM, James ML, Singh V, Clark WM, Norton C, Palesch YY, Yeatts SD, i-DEF Investigators
doi: 10.1016/S1474-4422(19)30069-9.
RECOMMENDED
Further Publications NeurologyFurther Publications Psychiatry
Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
Lancet.
CRASH-3 trial collaborators.
doi: 10.1016/S0140-6736(19)32233-0.
Multiple Sclerosis
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Respir Med.
Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP, focuSSced investigators.
doi: 10.1016/S2213-2600(20)30318-0.
Psychosis and Schizophrenia
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme
Lancet Psychiatry.
Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, Marques TR, Garibaldi G, Kapur S
doi: 10.1016/
Multiple Sclerosis
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Lancet Neurol.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D
doi: 10.1016/S1474-4422
RECOMMENDED
Multiple Sclerosis
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Lancet Neurol
Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD, SPI2 investigative teams.
doi: 10.1016/S1474-4422(20)30347-1
RECOMMENDED
Parkinson’s Disease
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial
Lancet Neurol.
LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C, SPAN-PD Study Investigators
doi: 10.1016/S1474-4422(18)30405-8.
RECOMMENDED
Migraine and Headache
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Lancet.
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB
doi: 10.1016/S0140-
RECOMMENDED
Further Publications NeurologyFurther Publications Psychiatry
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
doi: 10.1016/S1474-4422(20)30078-8.